Artelo Biosciences, Inc.
ARTL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001621221
No open-market purchases or sales by Artelo Biosciences, Inc. insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $132.0K in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Artelo Biosciences, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 7 | 6 | −1 |
| Shares | 47.6K | 39.3K | −8.32K (−17.5%) |
| Value | $110.8K | $78.4K | −$32.4K (−29.2%) |
New holders (1)
Institutions that held Artelo Biosciences, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| JPMorgan Chase & Co | 304 | $611 | 0.00% |
Sold out (2)
Institutions that held Artelo Biosciences, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| UBS Group AG | 2,378 | $5.52K |
| Creative Financial Designs Inc | 72 | $167 |